StockNews.com began coverage on shares of MediciNova (NASDAQ:MNOV - Free Report) in a research note issued to investors on Monday. The firm issued a hold rating on the biopharmaceutical company's stock.
MediciNova Stock Down 0.6 %
MNOV stock traded down $0.01 during midday trading on Monday, reaching $1.77. The company had a trading volume of 3,743 shares, compared to its average volume of 40,059. The stock has a 50 day moving average price of $1.62 and a 200 day moving average price of $1.47. MediciNova has a fifty-two week low of $1.12 and a fifty-two week high of $2.16. The firm has a market capitalization of $86.81 million, a PE ratio of -10.41 and a beta of 0.75.
MediciNova (NASDAQ:MNOV - Get Free Report) last issued its earnings results on Thursday, August 8th. The biopharmaceutical company reported ($0.05) EPS for the quarter, beating analysts' consensus estimates of ($0.06) by $0.01. Research analysts predict that MediciNova will post -0.23 EPS for the current year.
About MediciNova
(
Get Free Report)
MediciNova, Inc, a biopharmaceutical company, focuses on developing novel and small molecule therapeutics for the treatment of serious diseases with unmet medical needs in the United States. It is developing MN-166 (ibudilast), an oral anti-inflammatory and neuroprotective agent for treating neurological and other disorders, such as primary and secondary progressive multiple sclerosis, amyotrophic lateral sclerosis, chemotherapy-induced peripheral neuropathy, degenerative cervical myelopathy, glioblastoma, and substance dependence and addiction, as well as prevention of acute respiratory distress syndrome, and long COVID.
Featured Articles
Before you consider MediciNova, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and MediciNova wasn't on the list.
While MediciNova currently has a "hold" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Wondering when you'll finally be able to invest in SpaceX, StarLink, or The Boring Company? Click the link below to learn when Elon Musk will let these companies finally IPO.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
